Breastfeeding cuts ca risk in high-risk women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 9
Volume 18
Issue 9

Breastfeeding reduces breast cancer risk among women with a family history of breast cancer, according to a study. Observational studies suggest a relationship between lactation and premenopausal breast cancer risk.

Breastfeeding reduces breast cancer risk among women with a family history of breast cancer, according to a study. Observational studies suggest a relationship between lactation and premenopausal breast cancer risk.

In a prospective cohort study of the Nurses' Health Study II involving 60,075 premenopausal women, researchers found that among women with a first-degree relative with breast cancer, those who breastfed had a covariate-adjusted hazard ratio of 0.41. There was no association among women without a family history of breast cancer (Arch Intern Med 169:1364-1371, 2009).

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content